Physician profile
Elizabeth Strack
NPI 1164845814
$1,833.67
in general payments reported to CMS, 2019-2025
27 companies · $965 in 2025
The $965 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $12.11 · 2023: $392 · 2024: $304 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.70 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $290.61 | 2024-2025 | Minimed 780g, Simplera Sensor, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $210.91 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $163.29 | 2023-2025 | |
| Insulet Corporation | $159.37 | 2025 | Omnipod |
| Abbott Laboratories | $146.14 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.52 | 2021-2025 | Ofev |
| Nevro Corp. | $64.72 | 2023-2024 | Senza |
| Lilly USA, LLC | $64.28 | 2023-2025 | Taltz, Humulin, Mounjaro |
| Glaxosmithkline, LLC. | $57.60 | 2021-2023 | Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $48.82 | 2023-2025 | Gvoke Hypopen |
| Averitas Pharma INC. | $47.73 | 2023-2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $45.19 | 2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $43.72 | 2023-2024 | Acthar |
| Tandem Diabetes Care, INC. | $42.91 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $41.38 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $40.42 | 2021-2022 | |
| Abbvie INC. | $36.23 | 2025 | |
| Dexcom, INC. | $33.99 | 2023-2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $31.19 | 2025 | Yorvipath |
| Pfizer INC. | $29.80 | 2021 | |
| Grifols USA, LLC | $28.05 | 2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $27.52 | 2021 | |
| Merck Sharp & Dohme LLC | $22.46 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Actelion Pharmaceuticals US, INC. | $20.22 | 2024 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $18.95 | 2023 | Rexulti |
| Recordati_rare_diseases_inc. | $17.72 | 2023 | Panhematin |
| Amgen INC. | $16.93 | 2025 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Strack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.